Dr. Jonathan D. Parker

Reformed Christian | Family Physician | Fellow @AAFP | M.S., Clinical Research| @ABOMcert Certified |

[C. R. Wiley @crwiley1962]

Interesting.

[Roland-Garros @rolandgarros]

FONSECA TAKES OUT DJOKOVIC IN A FIVE-SET THRILLER 🇧🇷

#RolandGarros

[Endocrine Today @EndocrineToday]

⬇️ Adults with #obesity who lose weight with tirzepatide 10 mg or 15 mg may be able to maintain most of that weight loss if they reduce their dose to 5 mg, researchers reported at #ECO2026

Read more 👇

@EliLillyandCo @EASOObesity @GoHealio

https://t.co/k7GNuQD1iQ

[Ziyad Al-Aly, MD @zalaly]

Do GLP-1 drugs cause pancreatitis? Trials have not shown a clear increase. Reports from patients say yes. Observational studies are split.

We looked at this in 333,000 people.

The answer, in our new @BMJMedicine, is more interesting than yes or no.
https://t.co/QY2Jo2NkMY
🧵

[Dutch Rojas @DutchRojas]

In 1992, Congress wrote a paragraph to keep HIV clinics and rural hospitals alive.

By 2024, that paragraph was moving $81 billion a year.

In December 2025, a federal judge in Maine froze the reform plan, and 40+ pharmaceutical manufacturers, 20+ state legislatures, the Trump White House, the American Hospital Association, and your community hospital are now in open conflict over who controls the money next.

https://t.co/CyIRIuIjax

[Scott Isaacs @scottisaacsmd]

The genetics of obesity: This new @NatMetabolism review shows obesity is highly heritable, with more than 85 monogenic forms and over 1,000 GWAS loci, and is rapidly opening the door to true precision medicine (MC4R agonists, PRSs, genotype-guided therapies) for our patients living with obesity.
https://t.co/zfSgCkwx5x

[Scott Isaacs @scottisaacsmd]

Approximately 80% of HFpEF patients have obesity, driving cardiac remodeling, diastolic dysfunction, inflammation & skeletal muscle issues. Excellent review by Pandit et al on obesity's pivotal role in HFpEF pathophysiology, especially exercise intolerance.
https://t.co/SnywYWy1M7

[Patrick McEnroe @PatrickMcEnroe]

The college sports model is changing fast.

Lightning fast.

What we’re seeing in tennis is only the beginning.

I’ve been digging into this big time.

More coming…..soon

[Charlie Potter @Charlie_Potter]

Tide lands the nation's top QB.

[Dr. Jonathan D. Parker @JDParkerDO]

@DrAngelaFitch @ManOnThePen Unfortunately none of us have been.

[On The Pen™ @ManOnThePen]

So much of the GLP-1 industry STILL doesn’t understand, people (generally) don’t want to come off GLP-1 meds once they have experienced their benefits.

If you have ever dealt with legitimate obesity (not just a pesky few pounds), you would understand that effective treatment = freedom. Truly. Freedom from the all consuming, ever in front of you reality that no matter how hard you work, the weight will find a way back.

White knuckles release. The chain to the scale is broken. The prison door your to an overweight body that once held you captive is finally opened. Why would someone want to give that up?

$lly $nvo $vktx

[Michael Weintraub, MD @MWeintraubMD]

Weight loss itself rather than tissue-specific signalling of GLP1 is what carries the risk of advancing sarcopenia in older adults.

There is nothing unique to GLP1s that lead to lean mass loss, we see a similar effect in dietary modifications, other medications, or bariatric surgery.

⚖️ As GLP1 medicines have anorectic effects, the risk of using them must be carefully weighed against their potential benefits.

👴🏼👵🏼 These risk–benefit calculations need to differ in old versus young populations.

https://t.co/S02AYFNGVM
HT: @HenningLanger
#GLP1 #Weightloss #olderadults

[Michael Weintraub, MD @MWeintraubMD]

🚨 New press release on orforglipron's ACHIEVE-4 cardiovascular safety profile

💊 Orforglipron(Foundayo), the recently approved oral GLP-1 for obesity, here studied in adults with type 2 diabetes vs insulin glargine

⬇️ 24% 3-point MACE (heart attack, stroke, cardiovascular death)
⬇️ 16% 4-point MACE (heart attack, stroke, cardiovascular death, hospitalization with chest pain)
⬇️ 57% all-cause death

https://t.co/h0mtzvE0le

[Neil Floch MD @NeilFlochMD]

What is MOST fascinating is that insurance will still not pay for it. Amazing!

[Robert Lufkin MD @robertlufkinmd]

As a medical school professor, this may be the most unexpected finding in metabolic medicine right now.

A massive new study shows GLP-1 drugs like semaglutide don't just help with weight and blood sugar. They slash depression risk by 44% and anxiety disorders by 38%.

Hospitalizations dropped by 42%. Substance use-related sick leave fell by 47%.

Even suicidal tendencies declined.

These are staggering numbers that suggest metabolic health and mental health are far more connected than we ever taught in medical school.

This isn't just a weight loss drug producing side benefits. GLP-1 receptors are found throughout the brain. Preclinical research shows they directly affect mood, motivation, and reward circuits -- effects independent of weight loss.

It's more evidence for what I write about in "Lies I Taught in Medical School": the metabolic dysfunction driving obesity is the same dysfunction driving depression, anxiety, and addiction.

Full breakdown coming on the Health Longevity Secrets podcast.

Source: https://t.co/Jm6eSDpn9d

#GLP1 #MentalHealth #MetabolicHealth #Longevity #HealthLongevitySecrets

[Michael Mindrum, MD @MichaelMindrum]

GLP-1 medicines have quietly accumulated evidence across 6 organ systems beyond glucose + weight. A new review by Gonzalez-Rellan & @DanielJDrucker puts it all together. The common thread: anti-inflammatory mechanisms at play, partly independent of weight loss.

🫀 SELECT: 20% MACE reduction (HR 0.80); not explained by weight loss
🏥 HFpEF pooled: 31% CV death/HF hospitalization reduction (HR 0.69)
🩺 FLOW: 24% kidney progression reduction (HR 0.76) — dialysis, transplant, eGFR decline
🫁 SURMOUNT-OSA: AHI −25 to −29 events/hr vs placebo; FDA-approved for OSA
🦴 STEP 9 (knee OA): WOMAC pain −41.7 vs −27.5 placebo
🧪 MASH (ESSENCE): steatohepatitis resolution 63% vs 34%
🧠 EVOKE/EVOKE+ trials: semaglutide in early Alzheimer's — results expected 2025-26

🏁 https://t.co/EQBGlLVgct

[Scott Isaacs @scottisaacsmd]

New review by Maria Gonzalez-Rellan & Daniel Drucker focuses on the expanding benefits of GLP-1 meds like semaglutide & tirzepatide. Beyond glucose/weight control: ↓ CVD events, CKD progression, MASLD, OA, sleep apnea (via anti-inflammatory paths) partly weight-loss independent.
https://t.co/hRvaPYBr1X

[Prof Kamlesh Khunti @kamleshkhunti]

CGM reveals differences beyond HbA1c.

In GRADE study :
📊 Liraglutide & sitagliptin → highest Time in Range
⚠️ Glimepiride → most hypoglycaemia & variability
📉 Incretin therapies → lowest glucose variability (%CV)

CGM metrics provide deeper insight than HbA1c alone, helping personalise safer diabetes care.

https://t.co/RTNICPgZLV

@TBattelino

[Muhammad Aadil, MD @m_aadil]

This study is remarkable.

- 35% reduction in insulin resistance + 20% weight loss
- 91.5% completion rate (96% in semaglutide arm)
- No signal for psychiatric worsening (no PANSS difference vs placebo)

GLP-1 RAs are not just weight loss drugs.
They are metabolic interventions with psychiatric safety in high-risk populations.

[Scott Isaacs @scottisaacsmd]

Targeting MASH means targeting the whole spectrum, from insulin resistance and steatosis to inflammation, fibrosis and apoptosis. This figure maps pathogenic steps to therapeutic levers, highlighting why combination, mechanism based strategies are the future of #MASH and #MASLD care.
https://t.co/DVMslWicuT